Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies

Front Immunol. 2024 Apr 23:15:1373504. doi: 10.3389/fimmu.2024.1373504. eCollection 2024.

Abstract

Cancer is a very aggressive disease and one of mankind's most important health problems, causing numerous deaths each year. Its etiology is complex, including genetic, gender-related, infectious diseases, dysbiosis, immunological imbalances, lifestyle, including dietary factors, pollution etc. Cancer patients also become immunosuppressed, frequently as side effects of chemotherapy and radiotherapy, and prone to infections, which further promote the proliferation of tumor cells. In recent decades, the role and importance of the microbiota in cancer has become a hot spot in human biology research, bringing together oncology and human microbiology. In addition to their roles in the etiology of different cancers, microorganisms interact with tumor cells and may be involved in modulating their response to treatment and in the toxicity of anti-tumor therapies. In this review, we present an update on the roles of microbiota in cancer with a focus on interference with anticancer treatments and anticancer potential.

Keywords: cancer; immunotherapy; microbiome; microbiota; probiotics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Disease Progression*
  • Dysbiosis
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Microbiota
  • Neoplasms* / etiology
  • Neoplasms* / immunology
  • Neoplasms* / microbiology
  • Neoplasms* / therapy

Substances

  • Antineoplastic Agents

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. We acknowledge the support of the projects FDI-2024-F-484 and C1.2. PFE- CDI.2021-587/contract number 41PFE/2021.